Published articles

Published articles 1 records found  Search took 0.02 seconds. 
1.
12 p, 1.8 MB Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies / Leleu, Xavier (Service d'Hématologie et Thérapie cellulaire. CHU and Inserm) ; Beksac, M. (Department of Hematology. Ankara University) ; Chou, T. (Niigata Cancer Center Hospital) ; Dimopoulos, Meletios (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens School of Medicine) ; Yoon, S. S. (Department of Internal Medicine. Seoul National University) ; Prince, H. M. (Epworth Healthcare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ; Pour, L. (University Hospital Brno (República Txeca)) ; Shelekhova, T. (Clinic of Professional Pathology) ; Chari, Ajai (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica). Tisch Cancer Institute) ; Khurana, M. (Clinical Development. Oncology. Amgen Inc) ; Zhang, J. (Global Biostatistical Science. Amgen Inc) ; Obreja, M. (Global Biostatistical Science. Amgen Inc) ; Qi, M. (Hematology and Oncology. Janssen Research and Development. LLC) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Siegel, D. (John Theurer Cancer Center. Hackensack University Medical Center) ; Universitat Autònoma de Barcelona
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). [...]
2020 - 10.1080/10428194.2020.1832672
Leukemia and Lymphoma, 2020  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.